Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging-Guided Co-Delivery of siRNA and Doxorubicin to Drug-Resistant Cancer Cells

Guo, Daoxia; Ji, Xiaoyuan; Peng, Fei; Zhong, Yiling; Chu, Binbin; Su, Yuanyuan; He, Yao

doi:10.1007/s40820-019-0257-1

Cited by 40 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the emerging immunochemotherapy for cancer treatment, it is often encountered that the immune system fails to respond to the tumor cells [3], even when a large number of antitumor T cells are present [4]. It has been clear that the TME, featured with low pH values, insufficient blood flow, overproduced peroxide and hypoxia, plays a vital role in such failures for tumor immunosuppression [5][6][7]. Among these characteristics, the hypoxia has been reported as one of the most unfavorable features that tend to suppress the immunotherapeutic efficiency [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy

Wang

Fang

et al. 2019

Nano-Micro Lett.

View full text Add to dashboard Cite

HIGHLIGHTS • Self-oxygenation/degradable nanozyme reactors with core-shell structure were fabricated for relieving tumor hypoxia. • Intratumoral hypoxia alleviation and sensitization of immunochemotherapy using as-prepared nanozyme reactors was demonstrated in B16F10 melanoma tumor. ABSTRACT Recently emerged cancer immunochemotherapy has provided enormous new possibilities to replace traditional chemotherapy in fighting tumor. However, the treatment efficacy is hampered by tumor hypoxiainduced immunosuppression in tumor microenvironment (TME). Herein, we fabricated a self-oxygenation/degradable inorganic nanozyme with a core-shell structure to relieve tumor hypoxia in cancer immunochemotherapy. By integrating the biocompatible CaO 2 as the oxygen-storing component, this strategy is more effective than the earlier designed nanocarriers for delivering oxygen or H 2 O 2 , and thus provides remarkable oxygenation and long-term capability in relieving hypoxia throughout the tumor tissue. Consequently, in vivo tests validate that the delivery system can successfully relieve hypoxia and reverse the immunosuppressive TME to favor antitumor immune responses, leading to enhanced chemoimmunotherapy with cytotoxic T lymphocyte-associated antigen 4 blockade. Overall, a facile, robust and effective strategy is proposed to improve tumor oxygenation by using self-decomposable and biocompatible inorganic nanozyme reactor, which will not only provide an innovative pathway to relieve intratumoral hypoxia, but also present potential applications in other oxygen-favored cancer therapies or oxygen deficiency-originated diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy

Wang

Fang

et al. 2019

Nano-Micro Lett.

View full text Add to dashboard Cite

show abstract

“…On the other hand, it is of particular interest to develop functional silicon nanostructures for biological and biomedical applications over the years, since silicon nanostructures possess several intrinsic advantages like excellent optical/electronic properties, favorable biocompatibility, and good biodegradability [10][11][12][13][14][15][16][17]. Typically, zero-dimensional fluorescent silicon nanoparticles with robust photostability and negligible toxicity have been extensively explored for real-time and long-term bioimaging [18][19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Fluorescent Silicon Nanorods-Based Nanotheranostic Agents for Multimodal Imaging-Guided Photothermal Therapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Delivery materials derived from lipids, lipid-like materials (lipidoids), polymers, peptides, exosomes, inorganic nanoparticles, etc., have been designed and investigated. 2,8,[14][15][16][17][18][19][20][21][22] As a result, several modification patterns and delivery platforms have been employed in clinical studies. Here, the detailed evolution and advances in the modification and delivery technologies of siRNA are comprehensively summarized and discussed.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic siRNA: state of the art

Zhong

Weng

et al. 2020

Sig Transduct Target Ther

946

705

View full text Add to dashboard Cite

RNA interference (RNAi) is an ancient biological mechanism used to defend against external invasion. It theoretically can silence any disease-related genes in a sequence-specific manner, making small interfering RNA (siRNA) a promising therapeutic modality. After a two-decade journey from its discovery, two approvals of siRNA therapeutics, ONPATTRO ® (patisiran) and GIVLAARI™ (givosiran), have been achieved by Alnylam Pharmaceuticals. Reviewing the long-term pharmaceutical history of human beings, siRNA therapy currently has set up an extraordinary milestone, as it has already changed and will continue to change the treatment and management of human diseases. It can be administered quarterly, even twice-yearly, to achieve therapeutic effects, which is not the case for small molecules and antibodies. The drug development process was extremely hard, aiming to surmount complex obstacles, such as how to efficiently and safely deliver siRNAs to desired tissues and cells and how to enhance the performance of siRNAs with respect to their activity, stability, specificity and potential off-target effects. In this review, the evolution of siRNA chemical modifications and their biomedical performance are comprehensively reviewed. All clinically explored and commercialized siRNA delivery platforms, including the GalNAc (N-acetylgalactosamine)-siRNA conjugate, and their fundamental design principles are thoroughly discussed. The latest progress in siRNA therapeutic development is also summarized. This review provides a comprehensive view and roadmap for general readers working in the field.

show abstract

Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging-Guided Co-Delivery of siRNA and Doxorubicin to Drug-Resistant Cancer Cells

Cited by 40 publications

References 42 publications

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy

Fluorescent Silicon Nanorods-Based Nanotheranostic Agents for Multimodal Imaging-Guided Photothermal Therapy

Therapeutic siRNA: state of the art

Contact Info

Product

Resources

About